Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

In the first quarter, AbbVie acquired ImmunoGen and its flagship cancer therapy, ELAHERE. This acquisition will allow AbbVie ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Seaport names Lauren White as CFO. Ms. White most recently served as CFO at ImmunoGen prior to its acquisition by AbbVie for ...

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...